Stock comparison
LeMaitre Vascular
Thermo Fisher Scientific
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
TMO
Thermo Fisher Scientific
Market cap
$166.59B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | TMO | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 52C | LMAT |
| Benjamin Graham | 89A | 72B | LMAT |
| Philip Fisher | 81C | 39D | LMAT |
| Peter Lynch | 67B | 28F | LMAT |
| Joel Greenblatt | 56D | 48D | LMAT |
| Charlie Munger | 68D | 51D | LMAT |
| Terry Smith | 69D | 44D | LMAT |
Side-by-side metrics
| Metric | LMAT | TMO |
|---|---|---|
| Market cap | $2.23B | $166.59B |
| P/E (TTM) | 37.1x | 23.8x |
| EV/EBIT | 36.6x | 25.0x |
| ROIC (TTM) | 9.43% | 7.33% |
| Gross margin | 72.39% | 39.41% |
| Net margin | 24.35% | 15.18% |
| Revenue CAGR 5y | 12.75% | 3.25% |
| EPS CAGR 5y | 19.04% | -2.43% |
| Debt / Equity | 0.5x | 0.8x |
| Dividend yield | 0.84% | 0.4% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- EPS CAGR 5y19.04%vs -2.43%+113%
- Revenue CAGR 5y12.75%vs 3.25%+75%
- Dividend yield0.84%vs 0.4%+52%
- Gross margin72.39%vs 39.41%+46%
TMO leads on
- Market cap$166.59Bvs $2.23B+99%
- P/E (TTM)23.8xvs 37.1x+36%
- EV/EBIT25.0xvs 36.6x+32%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.